×
Correlates of Medication Adherence Among Patients With Bipolar Disorder: Results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) Study: A Nationwide Cross-Sectional Survey PDF
$ 40.00
Correlates of Medication Adherence Among Patients With Bipolar Disorder: Results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) Study: A Nationwide Cross-Sectional Survey PDF quantity
$ 40.00
×
Phenylpropanolamine Appears Not to Promote Weight Loss in Patients With Schizophrenia Who Have Gained Weight During Clozapine Treatment PDF
$ 40.00
Phenylpropanolamine Appears Not to Promote Weight Loss in Patients With Schizophrenia Who Have Gained Weight During Clozapine Treatment PDF quantity
$ 40.00
×
A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II) PDF
$ 40.00
A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II) PDF quantity
$ 40.00
×
Brief Cognitive Screener Detects Early Signs of Cognitive Decline in Anglo and Hispanic Patients PDF
$ 40.00
Brief Cognitive Screener Detects Early Signs of Cognitive Decline in Anglo and Hispanic Patients PDF quantity
$ 40.00
×
Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis PDF
$ 40.00
Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis PDF quantity
$ 40.00
×
Separation Anxiety and Measures of Suicide Risk Among Patients With Mood and Anxiety Disorders PDF
$ 40.00
Separation Anxiety and Measures of Suicide Risk Among Patients With Mood and Anxiety Disorders PDF quantity
$ 40.00
×
Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study PDF
$ 40.00
Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study PDF quantity
$ 40.00
×
Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study PDF
$ 40.00
Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart